177Lu-Dotatate versus high-dose long-acting octreotide for the treatment of patients with advanced, grade 1-2, well-differentiated gastroenteropancreatic neuroendocrine tumours (XT-XTR008-3-01): an open-label, randomised, phase III trial☆

DOI:10.1016/j.annonc.2025.08.3758
作者：J. Xu ,?J. Chen ,?S. Song ,?L. Song ,?R. Wang ,?J. Hao ,?X. Du ,?D. Cao ,?Y. Gao ,?X. Lan ,?A. Yang ,?W. Miao ,?H. Xu ,?Y. Chen ,?L. Li ,?H. Shi ,?X. Yuan ,?F. Ye ,?J. Wang ,?N. Xu ,?P. Wang
文献类型：期刊论文
补充材料：只需要正文